drugset
Drugs / ROPSACITINIB
last change Oct 2023 re-read 9 days ago

ROPSACITINIB

also known as PF-06826647 · PF-647

Small molecule targets TYK2 via inhibition

Developed for
psoriasis · hidradenitis suppurativa · ulcerative colitis
Investigated by
Pfizer

Trials 6

today NCT04591262 · Ph 1 NCT04209556 · Ph 2 NCT04092452 · Ph 2 NCT04134715 · Ph 1 NCT03895372 · Ph 2 NCT03210961 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT04591262 Nov 2020 → Jan 2021 — Pfizer Completed No outcome recorded
Phase 1 NCT04134715 Oct 2019 → Jan 2020 — Pfizer Completed No outcome recorded
Phase 1 NCT03210961 Jul 2017 → Jan 2019 psoriasis Pfizer Completed No outcome recorded
Phase 23 trials · 2 met primary
Phase 2 NCT04209556 Sep 2020 → Oct 2023 ulcerative colitis Pfizer Withdrawn No outcome recorded Stop: Business
Phase 2 NCT04092452 Dec 2019 → Jan 2022 hidradenitis suppurativa Pfizer Completed Met primary
Phase 2 NCT03895372 Jun 2019 → May 2020 psoriasis Pfizer Completed Met primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as ROPSACITINIB ChEMBL registry synonym — accepted as the source's own label CHEMBL4459585 ↗
Known as PF-06826647 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03210961 ↗
5

NCT04591262 ↗

NCT04209556 ↗

NCT04092452 ↗

NCT04134715 ↗

NCT03895372 ↗
Known as PF-647 ChEMBL registry synonym — accepted as the source's own label CHEMBL4459585 ↗
Action Inhibit “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4459585 ↗
1

“the TYK2 inhibitor PF-06826647” PMID 38279383 ↗ Dec 2020
Modality Small molecule — CHEMBL4459585 ↗
Route Oral “assessed once daily oral dosing of PF-06826647 in participants with plaque psoriasis” PMID 38279383 ↗ Dec 2020
Target TYK2 “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4459585 ↗